Inactive Instrument

ProLung, Inc.

LUNG

US74348P2092

Healthcare Facilities & Services

Robert W. Raybould Step Down from the Board of ProLung, Inc

November 27, 2019 at 01:59 am IST

ProLung, Inc. ('ProLung' or the 'Company') announced that Robert W. Raybould has stepped down from the board after approximately eight years of valuable service to the company.

Latest news about ProLung, Inc.

ProLung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23	CI
ProLung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	18/23/18	CI
ProLung, Inc. Auditor Raises 'Going Concern' Doubt	17/23/17	CI
ProLung, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
ProLung, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/22/16	CI
ProLung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	24/22/24	CI
ProLung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	15/22/15	CI
ProLung, Inc. Auditor Raises 'Going Concern' Doubt	15/22/15	CI
ProLung, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	13/21/13	CI
IONIQ Sciences, Inc. Announces the Appointment of Aaron B. Dorny to Its Board of Directors	07/21/07	CI
Prolung, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	17/21/17	CI
Prolung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	25/21/25	CI
Prolung, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	03/21/03	CI
Prolung, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	16/21/16	CI
ProLung, Inc. announced that it has received $0.182 million in funding	21/20/21	CI
ProLung, Inc. announced a financing transaction	03/20/03	CI
Prolung, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	26/20/26	CI
Prolung, Inc. Reports Earnings Results for the Year Ended December 31, 2019	16/20/16	CI
ProLung, Inc. has Changed its Name to IONIQ Sciences Inc	28/20/28	CI
ProLung, Inc. announced that it has received $3 million in funding	22/20/22	CI
Prolung, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	09/20/09	CI
ProLung, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	04/20/04	CI
Robert W. Raybould Step Down from the Board of ProLung, Inc	27/19/27	CI
ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% Sensitivity and 74% Specificity	04/19/04	CI
ProLung, Inc. Announces the Appointment of Leavitt Partners and Rich Mckeown to its Board of Directors	13/19/13	CI

Prolung, Inc. is a development-stage medical technology company specializing in predictive analytic, early stage lung cancer risk testing, which refer to as the ProLung Test. The Company's ProLung Test is developed to immediately assess the risk of malignancy in lung nodules found in the chest by a Computed Tomography (CT) scan. The Company's Lead Product is ProLung Test, which is designed to evaluate the risk of lung cancer in patients with lung nodules in well-controlled clinical trials. The ProLung Test includes components, such as ProLung System and ProLung Test Kit. ProLung System consists of the probe, scanner, tower, monitor, and keyboard which are all medical grade components. This component is available for sale in English, French, German, Spanish, and Italian versions. ProLung Test Kit includes six diaphoretic electrodes, one probe tip and one moistening sponge.

Sector

Healthcare Facilities & Services

More about the company

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
SONIC HEALTHCARE LIMITED	-18.17%	8.53B
RADNET, INC.	+65.89%	4.26B
DR. LAL PATHLABS LIMITED	+6.56%	2.71B
SYNLAB AG	-1.93%	2.63B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-57.14%	1.72B
NEOGENOMICS, INC.	-19.16%	1.67B
FLEURY S.A.	-20.01%	1.45B
METROPOLIS HEALTHCARE LIMITED	+15.38%	1.19B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-50.40%	1.01B

Medical & Diagnostic Laboratories

ProLung, Inc.

Equities

LUNG

US74348P2092

Healthcare Facilities & Services

Robert W. Raybould Step Down from the Board of ProLung, Inc

Latest news about ProLung, Inc.

Chart ProLung, Inc.

Company Profile

Sector Medical & Diagnostic Laboratories